Acta Med. 1998, 41: 99-108
https://doi.org/10.14712/18059694.2019.173
Central Cholinergic Nervous System and Cholinergic Agents
References
1. Br J Pharmacol 1947; 2: 56-8.
ED, Feldberg W, Kilby BA. The cholinesterase inhibition action of fluorophosphonates.
2. J Pharmacol 1991; 43:413-44.
JA, Reinert M. Pharmacological action of some analogues of physostigmine.
3. Soc Neurosci Abstr 1995; 21:2040.
J, Gurwitz D, Fisher A et al. Novel muscarinic M1 receptor agonists promote survival of CNS neurons in primary cell culture.
4. Angevine JB, Jr., Cotman CW. Principles of Neuroanatomy. New York:Oxford.Univ.Press, 1981.
5. J Pharm Pharmacol 1971; 23:90-7.
< RB. Differences in the stereoselectivity of closely related compounds: A reinvestigation of enantiomers of procyclidine, benzhexol and their metho- and etho-salts. https://doi.org/10.1111/j.2042-7158.1971.tb08618.x>
6. J Med Chem 1973; 16:564-6.
< RB, Harrison M, Ison RR et al. Epimeric forms of quaternary derivatives of atropine. https://doi.org/10.1021/jm00263a037>
7. Science 1982; 217:408-17.
< RT, Dean III, RL, Beer B et al. The cholinergic hypothesis of geriatric memory dysfunction. https://doi.org/10.1126/science.7046051>
8. Adv Drug Res 1965; 2:143-72.
A, Brimblecombe RW. Muscarinic receptors in the peripheral and central nervous system.
9. Soc Neurosci Abstr 1984; 10:256.
F, Garcia J. The role of hippocampal cholinergic activity in taste-potentiated odor aversion learning.
10. J Nerv Ment Dis 1960; 131:256-9.
< RR. Psychiatric manifestation of artane toxicity. https://doi.org/10.1097/00005053-196009000-00008>
11. Int J Neuropharm 1968; 7:15-21.
< RW, Green DM. The peripheral and central action of some anticholinergic substances. https://doi.org/10.1016/0028-3908(68)90050-6>
12. J Pharm Pharmacol 1979; 22:951-3.
< RW, Green D, Inch D. A comparison of the stereochemical requirements of cholinergic and anticholinergic drugs. https://doi.org/10.1111/j.2042-7158.1970.tb08484.x>
13. Nature 1985; 315:474-7.
< A, Unwin PNT. Quaternary structure of the acetylcholine receptor. https://doi.org/10.1038/315474a0>
14. Brown JH. Atropine, scopolamine and related antimuscarinic drugs. In: Goodman Gilman A, Rall TW, Neis AS et al., eds.: Goodman and Gilmans the Pharmacological Basis of Therapeutics. New York:Pergamon Press, 1990:150-67.
15. Br J Pharmacol 1980; 70:577-92.
< DA, Fatherazi S, Garthwaite J. et al. Muscarinic receptors in rat sympathetic ganglia. https://doi.org/10.1111/j.1476-5381.1980.tb09777.x>
<PubMed>
16. Drugs Aging 1997; 10:234-9.
< HM, Benfield P. Donepezil. https://doi.org/10.2165/00002512-199710030-00007>
17. Burger A. ed.. Drugs Affecting the Central Nervous System. New York:Marcel Dekker, 1968.
18. Br J Pharmacol 1963; 21:137-42.
RL. The mode of action of pyridostigmine on the guinea-pig trachealis muscle.
19. TIPS 1987; 8:459-65.
J, Cirqudat J, Dennis M. The nicotinic acetylcholine receptor: Molecular architecture of a ligand-regulated ion channel.
20. J Pharm Pharmacol 1985; 37:656-8.
< LK, Mitchelson F. Comparison of the affinity constants of some muscarinic receptor antagonists with their displacements of [3H]-quinuclidinyl benzilate binding in atrial and ileal longitudinal muscle of the guinea-pig. https://doi.org/10.1111/j.2042-7158.1985.tb05106.x>
21. Br J Psychiatry 1981; 138:46-50.
< JE, Phil M, Shering A et al.. Physostigmne and arecoline: Effects of intravenous infusions in Alzheimer presenile dementia. https://doi.org/10.1192/bjp.138.1.46>
22. Pharmacol Ther 1991; 52:423-43.
< JA, Perry EK. Dementia: The neurochemical basis of putative transmitter oriented therapy. https://doi.org/10.1016/0163-7258(91)90035-K>
23. Science 1983; 219:1184-90.
< JT, Price DL, De Jong ML. Alzheimers disease: A disorder of cortical cholinergic inervation. https://doi.org/10.1126/science.6338589>
24. Ann Emerg Med 1981; 10:98-100.
< DH, Rosen P. Abuse of antiparkinsonian drugs. https://doi.org/10.1016/S0196-0644(81)80347-2>
25. Br J Psychiatry 1984; 145:300-3.
< JA, Mullen PE. A study of benzhexol abuse. https://doi.org/10.1192/bjp.145.3.300>
26. Neurology 1996; 47:876-83.
< JL, Kaufer D. Neuropsychiatric aspects of Alzheimers disease. The cholinergic hypothesis revisited. https://doi.org/10.1212/WNL.47.4.876>
27. J Pharmacol Exp Ther 1914; 6:147-90.
HH. The action of certain esters of choline and their relation to muscarine.
28. Danielli JE, Moran JF, Triggle DJ. eds. Fundamental Concepts in Drug-Receptor Interaction. New York:Acad. Press, 1970.
29. Gen Pharmacol 1986; 17:715-20.
< YT, Brown HD, Chattapadhyay SK. Substrate-ligand interactions with acetylcholinesterase and energetics of binding. https://doi.org/10.1016/0306-3623(86)90306-X>
30. Davis KL, Berger PA, eds. Brain Acetylcholine and Neuropsychiatric Disease. New York:Plenum Press, 1979.
31. TIPS 1991; 12:34-40.
ES, Connolly J, Rogers SW et al. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors.
32. J Clin Psychopharmacol 1988; 8:14-22.
SC. Antimuscarinic agents as substance of abuse: a review.
33. Drug Therapy 1976; 99-103.
A, Sovner RD. Neuroleptic-induced extrapyramidal side effects. A plan for rational treatment.
34. Drachman DA. Alzheimers Disease: Senile Dementia and Related Disorders. Vol.7. New York:Raven Press, 1978: 141-8.
35. Mol Pharmacol 1985; 28:107-19.
FJ, Jenden DJ. The binding of a 2-chloroethylamine derivative of oxotremorine (BM 123) to muscarinic receptors in the rat cerebral cortex.
36. Eto M. Organophosphorus Pesticides: Organic and Biological Chemistry. Cleveland:CRC Press, 1974.
37. Fest C, Schmidt KJ. The Chemistry of Organophosphorus Pesticides. Berlin:Springer-Verlag, 1973.
38. Acta Psychiatr Scand 1987; 75:91-4.
< RZ. Trihexyphenidyl abuse. Therapeutic implications for negative symptoms of schizophrenia? https://doi.org/10.1111/j.1600-0447.1987.tb02757.x>
39. Drug. News Prosp. 1994; 7:453-64.
A, Barak D. Progress and perspectives in new muscarinic agonists.
40. Voj Zdrav Listy 1977; 46:65-8.
J. Bojové otravné látky se zneschopňujícím účinkem typu BZ.
41. Fusek J. Zneschopňující otravné látky s psychotomimetickým účinkem. Učební texty Hradec Králové:VLVDÚ , sv. 206, 1984.
42. Life Sci 1986; 38:1663-72.
< A, Micheletti R, Montagna E. Cardioselective profile of AF-DX116, a muscarinic M2-receptor antagonist. https://doi.org/10.1016/0024-3205(86)90410-8>
43. J Pharmacol Exp Ther 1985; 232:608-16.
DW, Wolfe BB. Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase.
44. Neuro Report 1995; 6:485-8.
D, Haring R, Pinkas-Kramarski R et al. NGFdependent neurotrophic-like effects of AF102B, a M1 muscarinic agonist, in PC12M1 cells.
45. J Neuropathol Exp Neurol 1984; 43:1-21.
< JC, Struble RG, Whitehause PJ et al. Topography of the magno-cellular basal forebrain system in human brain. https://doi.org/10.1097/00005072-198401000-00001>
46. Hollister LE. Pharmacology and Toxicology of Psychotomimetics. Handbook of Experimental Pharmacology. Vol.55/III. Berlin, Heidelberg, New York:Springer-Verlag, 1981.
47. Holmstedt B. The ordeal bean of old calabar: the pageant of Physostigma venenosum in medicine. In: Swain T (Ed.): Plants in the Development of Modern Medicine, Cambridge:Harvard Univ.Press, 1972:303-60.
48. Obrana vlasti 1973; 5:17-1.
V. Současný vojenský význam látek vyvolávajících dočasné psychické zneškodnění.
49. J Biol Chem 1993; 268:22959-62.
AY, Haass C, Nitsch RN et al. Activation of protein kinase C inhibits cellular production of the amyloidprotein.
50. Int Rev Neurobiol 1974; 16:67-144.
< TD, Brimblecombe RW. Antiacetylcholine drugs: Chemistry, Stereochemistry and Pharmacology. https://doi.org/10.1016/S0074-7742(08)60195-6>
51. Biochemistry 1969; 8:1889-95.
< F, Main AR. Effect of charge on carbamylation and binding constants of eel acetylcholinesterase in reaction with neostigmine and related carbamates. https://doi.org/10.1021/bi00833a018>
52. Eur J Pharmacol 1985; 109:311-3.
< G, Sulakhe PV. Gallamine binding to heart M2 cholinergic receptors does not antagonize cholinergic inhibition of adenylate cyclase in isolated plasma membrane. https://doi.org/10.1016/0014-2999(85)90439-X>
53. Behav Genet 1995; 25:149-59.
< JR, Nordberg A. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimers disease and Parkinsons disease. https://doi.org/10.1007/BF02196924>
54. Drug Dev Res 1984; 4:125-42.
< DS, Risch SC. Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress. https://doi.org/10.1002/ddr.430040202>
55. Dis Nerv Syst 1977; 38:353-5.
T. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication.
56. Jenden DJ, ed. Cholinergic Mechanisms and Psychopharmacology. New York:Plenum Press, 1977.
57. Neurotransmissions 1987; 3:1-5.
C, Rzeszotarski WJ. Cholinergic agents.
58. N Engl J Med 1986; 314:964-73.
< R. Alzheimers disease. https://doi.org/10.1056/NEJM198604103141506>
59. Neurosci Behav Rev 1983; 7:73-85.
< RL, Homick JL. Motion sickness: A modulatory role for the central cholinergic nervous system. https://doi.org/10.1016/0149-7634(83)90008-8>
60. Physiol Rev 1974; 54:418-540.
< K. Chemical nature of synaptic transmission in vertebrates. https://doi.org/10.1152/physrev.1974.54.2.418>
61. J Am Chem Soc 1961; 83:1458-60.
< RM, Laidler KJ. Molecular mechanisms for hydrolytic enzyme action. IV. Structure of the active center and the reaction mechanism. https://doi.org/10.1021/ja01467a044>
62. Folia Pharmacol Jap 1986; 88:299-307.
< H. Effects of amiridin on ambulatory activity and discrete shuttle avoidance response in mice. https://doi.org/10.1254/fpj.88.299>
63. Hosp Community Psychiatry 1991; 42:580-1.
W, Pinsky D, Salzman C. Abuse and misuse of anticholinergic medications.
64. Acta Pharm Suec 1984; 21:271-94.
B, Kerstin C, Dahlbom R. Troxonium-like inhibitors of the high affinity uptake of choline in mouse brain synaptosomes in vitro.
65. J Neurochem 1995; 64:2491-9.
< L, Pinkas-Kamarksi R, Sokolovsky M et al. Activation of muscarinic receptors inhibits apoptosis in PC12M1 cells. https://doi.org/10.1046/j.1471-4159.1995.64062491.x>
66. Can J Chem 1986; 64:837.
< JS, Yu CM, Zhou YZ. The structure of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. https://doi.org/10.1139/v86-137>
67. Am J Psychiatry 1977; 134:809-11.
K. Abuse of antiparkinsonian drugs by psychiatric patients.
68. Maelicke A, ed. Nicotinic Acetylcholine Receptor. Structure and Function. NATO Series H. New york: Springer-Verlag, 1986.
69. CNS Drugs 1006; 5:190-9.
< PA, Stoner SC, Bunker MT. Anticholinergic drug abuse and misuse. Epidemiology and therapeutic implications. https://doi.org/10.2165/00023210-199605030-00005>
70. Martinez-Murillo R, Rodrigo J. The localization of cholinergic neurons and markers in the CNS. In: Stone TW, ed. CNS Neurotransmitters and Neuromodulators: Acetylcholine. New York:CRC Press, 1995:1-37.
71. Trends Pharmacol Sci 1985; 6:387-8.
< JK Fishman EB. Presynaptic acetylcholinesterase. https://doi.org/10.1016/0165-6147(85)90181-6>
72. Prog Brain Res 1993; 98:139-46.
< J, Sussman J, Bon S et al. Structure and functions of acetylcholinesterase and butyrylcholinesterase. https://doi.org/10.1016/S0079-6123(08)62391-2>
73. Matoušek J, Bajgar J, eds. Extrémně toxické nízkomolekulární syntetické jedy. Hradec Králové:VLVDÚ, 1979.
74. Matsumura F, ed. Differential Toxicities of Insecticides and Halogenated Aromatics. International Encyclopedia of Pharmacology and Therapeutics. Section 113. Oxford: Pergamon Press, 1984.
75. J Comp Neurol 1983; 214:170-97.
< MM, Mufson EJ, Lewey AI et al. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hyppothalamus in the rhesus monkey. https://doi.org/10.1002/cne.902140206>
76. Ann Neurol 1986; 19:144-51.
< MM, Volicer L, Marquis JK et al. Systematic regional differences in the cholinergic innervation of the primate cerebral cortex: distribution of enzyme activities and some behavioral implications. https://doi.org/10.1002/ana.410190206>
77. Am J Psychiatry 1988; 145:342-5.
PS, Rickardson JS, Jyn CA et al. Association of low serum anticholinergic levels and cognitive impairment in elderly presurgical patients.
78. J Mol Biol 1963; 6:306-29.
< J., Changeux J-P, Jacob F. Allosteric proteins and cellular control systems. https://doi.org/10.1016/S0022-2836(63)80091-1>
79. J Mol Biol 1965; 12:88-118.
< J, Wyman J, Changeux J.-P. On the nature of allosteric transitions: a plausible model. https://doi.org/10.1016/S0022-2836(65)80285-6>
80. Drugs N Prospect 1989; 2:397-8.
WH, Hershenson FM. Potential therapeutic strategies for senile cognitive disorders.
81. Exp Neurol 1983; 82:43-54.
< E, Infante C, Gonzalez M. Rotational behavior in the cat induced by electrical stimulation of the pulvinar lateralis posterior nucleus complex: Role of the cholinergic system. https://doi.org/10.1016/0014-4886(83)90241-8>
82. Science 1992; 258:304-7.
< RN, Slack BE, Wurtman RJ et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. https://doi.org/10.1126/science.1411529>
83. J Reprod Fert Suppl 1993; 46:145-54.
A. Neuronal nicotinic receptors and their implications in aging and neurodegenerative disorders in mammals.
84. Nordberg A, Adam A, Nilsson L et al. Heterogeneous cholinergic nicotinic receptors in the CNS. In: Clementi F, Batti C, Sher E, eds. Nicotinic Acetylcholine Receptors in the Nervous System.. NATO Series H., New York:Springer-Verlag, 1988:331-50.
85. J Neurosci Res 1992; 31:103-11.
< A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia. https://doi.org/10.1002/jnr.490310115>
86. Prog Brain Res 1989; 79:1-366.
A, Fuxe K, Holmstedt B et al. Nicotinic receptors in the CNS - their role in synaptic transmission.
87. Prog Brain Res 1989; 79:353-62.
< A, Nilson-Hakensson L, Adam A et al. The role of nicotinic receptors in the pathophysiology of Alzheimers disease. https://doi.org/10.1016/S0079-6123(08)62495-4>
88. Neurosci Lett 1996; 72:115-9.
< A, Winblad B. Reduced number of 3H-nicotine and 3H-acetylcholine binding sites in the frontal cortex of Alzheimer brains. https://doi.org/10.1016/0304-3940(86)90629-4>
89. OBrien RD. Toxic Phosphorus Esters. Chemistry, Metabolism, and Biological Effects. New York and London:Acad.Press, 1960.
90. Jpn J Pharmacol 1990; 53:211-20.
< Y, Natori K, Irie T et al. Effect of novel CNSselective cholinesterase inhibitor, SM-10888, on habituation and passive avoidance response in mice. https://doi.org/10.1254/jjp.53.211>
91. Ottoson D. Physiology of the Nervous System. New York:Oxford Univ Press, 1983.
92. Soc Neurosci Abstr 1984; 10:1177.
J, Sahley TL, Normansell LN. Cholinergic control of social play.
93. Collect Czech Chem Commun 1976; 41:816-24.
< J, Bajgar J, Bielavský J et al. Kinetics of inhibition of cholinesterases by 1,2,3,4-tetrahydro-9-aminoacridine in vitro. https://doi.org/10.1135/cccc19760816>
94. Collect Czech Chem Commun 1980; 45:966-76.
< J, Bajgar J, Bielavský J. Kinetics of inhibition of acetylcholinesterase by 9-hydrazino-1,2,3,4-tetrahydroacridine and 9-amino-10-methyl-1,2,3,4-tetrahydroacridinium in vitro. https://doi.org/10.1135/cccc19800966>
95. Homeostasis 1994; 35:299-301.
J, Bielavský J, Fusek J. Advances in synthesis of tacrine derivatives as potential drugs for treatment of Alzheimers disease.
96. Proc Natl Acad Sci USA 1980; 77:708-12.
< P, Datta N. Anticholinergic substances: A single constituent conformation. https://doi.org/10.1073/pnas.77.2.708>
<PubMed>
97. Pepeu G, Ladinsky H, eds. Cholinergic Mechanisms: Phylogenetic Aspects, Central and Peripheral Synapses, and Clinical Significance. New York:Plenum Press, 1981.
98. Age Aging 1980; 9:1-8.
< EK. The cholinergic system in old age and Alzheimers disease. https://doi.org/10.1093/ageing/9.1.1>
99. J Pharmacol Exp Ther 1952; 104:284-90.
LO, Benson WM, Stefko PL. Spasmolytic action of bicyclic basic alcohol esters.
100. Biochem Pharmacol 1979; 27:1117-24.
< M, Yaavetz B, Kloog Y et al. In vivo and in vitro studies on the antimuscarinic activity of some aminoesters of benzilic acid. https://doi.org/10.1016/0006-2952(78)90438-0>
101. Robinson JP. The Problem of Chemical and Biological Warfare. Vol.II. CB Weapons Today. Stockholm:SIPRI, Almqvist and Wikselle, 1973.
102. Pol J Pharmacol 1981; 33:177-84.
Z, Herbut M. Role of the cholinergic system in foot shock induced mouse aggression.
103. Vojnosanit Pregl 1974; 6:393-6.
N, Kušič R, Vojvodič V et al. Psychochemical war gases of BZ type.
104. Drugs Fut 1987; 12:531-2.
J. Huperzine A.
105. Brain Res 1983; 289:169-75.
< RJ, Ball M., Colhoun RH. Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimers disease. https://doi.org/10.1016/0006-8993(83)90017-3>
106. Schliebs R, Robner S. Distribution of muscarinic acetylcholine receptors in the CNS. In: Stone TW, ed. CNS Neurotransmitters and Neuromodulators: Acetylcholine. Boca Raton, 1995:67-83.
107. Scheibel AB, Wechsler AF, Brazier MHB, eds. The Biological Substrates of Alzheimers Disease. Orlando: Acad. Press, 1986.
108. J Neurochem 1993; 61:2225-32.
< DW, Kuchel GA, Zigmond RE. Decline in response to nicotine in aged rat striatum: Correlation with a decrease in a subpopulation of nicotinic receptors. https://doi.org/10.1111/j.1471-4159.1993.tb07463.x>
109. Life Sci 1986; 38:1021-9.
< AS, Kohlstaedt EV. Physostigmine effects in Alzheimers disease: Relationship to dementia severity. https://doi.org/10.1016/0024-3205(86)90236-5>
110. J Neurochem 1976; 26:909-22.
< JR, Atweh S, Kuhar MJ. Sodium-dependent high affinity choline uptake: A regulatory step in the synthesis of acetylcholine. https://doi.org/10.1111/j.1471-4159.1976.tb06472.x>
111. Sitaram N, Gillin MC. Choline chloride and arecoline: Effects on memory and sleep in man. In: Barbeau A, Growdon JW, Wurtman RJ, eds. Nutrition and the Brain, Vol. 5: Choline and Lecithin in Brain Disorders. New York: Raven Press, 1979:367-75.
112. Trends Biochem Sci 1992; 17:353-8.
< , Guatt A, Loewenstein Y et al. Excavations into the active-site gorge of cholinesterases. https://doi.org/10.1016/0968-0004(92)90314-Y>
113. J Med Chem 1975; 18:1056-61.
< GM, Mednick ML, Maddox J et al. A hydrophobic binding site in acetylcholinesterase. https://doi.org/10.1021/jm00245a002>
114. J Am Chem Soc 1952; 74:2219-21.
< LH, Kaiser S. Antispasmotics. II. Esters of basic bicyclic alcohols. https://doi.org/10.1021/ja01129a020>
115. N Engl J Med 1986; 315:1241-5.
< WK, Majovski LV, Marsh GM et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. https://doi.org/10.1056/NEJM198611133152001>
116. Szász G. Pharmaceutical Chemistry of Adrenergic and Cholinergic Drugs. CRC Press:Boca Raton, 1985:103.
117. N Engl J Med 1983; 308:720.
LJ, Fuld PA. Memory enhancement with oral physostigmine in Alzheimers disease.
118. Dementia 1990; 1:46-51.
T, Bickel U, Fischer JP et al. Galanthamine hydrobromide in a long-term treatment of Alzheimers disease.
119. Canad J Chem 1962; 40:1201-15.
< DJ, Belleau B. Studies on the chemical basis for cholinomimetic and cholinolytic activity. Part I. The synthesis and configuration of quaternary salts in the 1,3-dioxolane and oxazoline series. https://doi.org/10.1139/v62-183>
120. J Neurochem 1985; 44:11-24.
< S. Regulation of acetylcholine synthesis in the brain. https://doi.org/10.1111/j.1471-4159.1985.tb07106.x>
121. Am J Psychiatry 1992; 149:1393-4.
L, Carr S, Hoag E et al. Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium.
122. J Neurol Sci 1989; 90:1-21.
< A, Miyoshi K. Effects of cholinergic drugs on learning impairment in ventral globus pallidus-lesioned rats. https://doi.org/10.1016/0022-510X(89)90041-5>
123. Collect Czech Chem Commun 1985; 50:978-83.
< J, Kovář J, Šimánek V. Interaction of quaternary aromatic isoquinoline alkaloids with acetylcholinesterase. https://doi.org/10.1135/cccc19850978>
124. J Neurogenet 1984; 1:153-8.
< JHF, Boersma HJLM. A genetically controlled hippocampal transmitter system regulating exploratory behavior in mice. https://doi.org/10.3109/01677068409107080>
125. Vander AJ, Sherman JH, Luciano DS. Human Physiology. Fifth Edition. New York:McGraw-Hill Publ.Comp., 1990.
126. News Physiol Sci 1996; 11:202-8.
C. Changeux J-P. Neuronal nicotinic acetylcholine receptors in the brain.
127. Remedia 1993; 3:376.
O. Anticholinergika. Riziko pro rozum.
128. Waser PG. Cholinergic Mechanisms. New York:Reven Press, 1975.
129. Biochem Pharmacol 1977; 26:757-61.
< P, Wilkinson RG. The interaction of carbamates with acetylcholinesterase. https://doi.org/10.1016/0006-2952(77)90220-9>
130. Bull WHO 1971; 44:203-13.
MHJ. Toxicity of carbamates to insects.
131. Mol Pharmacol. 1975; 11:671-89.
H, Maayani S, Srebrenik S et al. A theoretical and experimental study of the semirigid cholinergic agonist 3-acetoxyquinuclidine.
132. Wenke M, Mráz M, Hynie S. Farmakologie pro lékaře. Vol.I., Praha:Avicenum, Zdravotnické nakladatelství, 1983: 456.
133. Brain Res 1986; 371:146-51.
< PJ, Martino AM, Antuano PG et al. Nicotinic acetylcholine binding sites in Alzheimers brain. https://doi.org/10.1016/0006-8993(86)90819-X>
134. Ann Neurol 1981; 10:122-6.
< PJ, Price DL, Clark AW et al. Alzheimers disease: Evidence for a selective loss of cholinergic neurons in the nucleus basalis. https://doi.org/10.1002/ana.410100203>
135. Ann NY Acad Sci 1967; 144:664-74.
< IB. Conformational changes in acetylcholinesterase. https://doi.org/10.1111/j.1749-6632.1967.tb53802.x>
136. J Biol Chem 1961; 236:1498-1500.
IB, Hatch MA, Ginsburg S. Carbamyl derivatives of acetylcholinesterase.
137. Wonnacott S, Russell MAH, Stolerman IB. Nicotine Psychopharmacology - Molecular, Cellular and Behavioural Aspects. Oxford:Oxford Univ. Press., 1990.
138. Compr Psychiatry 1974; 15:439-42.
< GE, OBrien CP. Anticholinergic toxic psychosis in drug abusers treated with benztropine. https://doi.org/10.1016/0010-440X(74)90043-1>
139. Soc Neurosci Abstr 1988; 14:59.
Y, Araki S, Kosasa T et al. Neurochemical studies of E-2020 a novel centrally acting acetylcholinesterase inhibitor.
140. New Drugs Clin Remedies 1986; 5:260-2.
SL. Therapeutic effects of huperzine A on the aged with memory impairment.
141. Int J Develop Neurosci 1990; 8:715-721.
< X, Wahelstrm G, Nordberg A. Inf luence of development and aging in nicotinic receptor subtypes in rodent brain. https://doi.org/10.1016/0736-5748(90)90065-A>